Sara Conroy

Dr. Sara Conroy

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 August 2020 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
SCSara Conroy
Sara Conroy
EMEleanor J. Murray
Eleanor J. Murray
Summary: What does it mean to control for confounding, and when do we actually need to do it? To answer this, we need a well-defined research question, driven by the goal of the study. For descriptive goals, we explain that confounding adjustment is often not just unnecessary but can be harmful.

1 March 2022 in The Journal of Pediatrics
Verified
Journal Article
Closed access
MKMatthew J. Kielt
Matthew J. Kielt
JLJ. Wells Logan
J. Wells Logan
CBCarl H. Backes
Carl H. Backes
SCSara Conroy
Sara Conroy
KRKristina M. Reber
Kristina M. Reber
LNLeif D. Nelin
Leif D. Nelin

22 September 2023 in Cancer Research Communications
Verified
Journal Article
Open access
PDF file
TBTheodore M. Brasky
Theodore M. Brasky
ANAlison M. Newton
Alison M. Newton
SCSara Conroy
Sara Conroy
AAAnita Adib
Anita Adib
NANeema C. Adley
Neema C. Adley
JKJessica L. Krok-Schoen
Jessica L. Krok-Schoen
Symptoms such as pain, nausea, and anxiety are common in individuals with cancer. Treatment of these issues is often challenging. Cannabis products may be helpful in reducing the severity of these symptoms. While some studies include data on the prevalence of cannabis use among patients with cancer, detailed data remain limited, and none have reported the prevalence of cannabidiol (CBD) use in this population.Adult patients with cancer attending eight clinics at a large, NCI-designated Comprehensive Cancer Center completed a detailed, cannabis-focused questionnaire between 2021 and 2022. Eligible participants were diagnosed with invasive cancer and treated in the past 12 months. Summary statistics were calculated to describe the sample regarding cannabis use.Approximately 15% (n = 142) of consented patients (n = 934) reported current cannabis use (defined as use within the past 12 months). Among which, 75% reported cannabis use in the past week. Among current cannabis users, 39% (n = 56; 6% overall) used CBD products. Current users reported using cannabis a median of 4.5 (interquartile range: 0.6–7.0) days/week, 2.0 (1.0–3.0) times per use/day, and for 3 years (0.8–30.0). Use patterns varied by route of administration. Patients reported moderate to high relief of symptoms with cannabis use.This study is the most detailed to date in terms of cannabis measurement and provides information about the current state of cannabis use in active cancer. Future studies should include complete assessments of cannabis product use, multiple recruitment sites, and diverse patient populations.Significance: Clinicians should be aware that patients are using cannabis products and perceive symptom relief with its use.

21 April 2021 in The Journal of Pediatrics
Verified
Journal Article
Closed access
LPLeeann R. Pavlek
Leeann R. Pavlek
BRBrian K. Rivera
Brian K. Rivera
CSCharles V. Smith
Charles V. Smith
JRJoanie Randle
Joanie Randle
CHCory Hanlon
Cory Hanlon
CBCarl H. Backes
Carl H. Backes

15 February 2022 in Neurology
Verified
Journal Article
Closed access
PDF file
AZAlberto A. Zambon
Alberto A. Zambon
MWMegan A. Waldrop
Megan A. Waldrop
RARoxane Alles
Roxane Alles
RWRobert B. Weiss
Robert B. Weiss
SCSara Conroy
Sara Conroy
TPThe United Dystrophinopathy Project
The United Dystrophinopathy Project
Background and Objectives To describe the phenotypic spectrum of dystrophinopathy in a large cohort of individuals with DMD exon 2 duplications (Dup2), who may be particularly amenable to therapies directed at restoring expression of either full-length dystrophin or nearly full-length dystrophin through utilization of the DMD exon 5 internal ribosome entry site (IRES). Methods In this retrospective observational study, we analyzed data from large genotype–phenotype databases (the United Dystrophinopathy Project [UDP] and the Italian DMD network) and classified participants into Duchenne muscular dystrophy (DMD), intermediate muscular dystrophy (IMD), or Becker muscular dystrophy (BMD) phenotypes. Log-rank tests for time-to-event variables were used to compare age at loss of ambulation (LOA) in participants with Dup2 vs controls without Dup2 in the UDP database and for comparisons between steroid-treated vs steroid-naive participants with Dup2. Results Among 66 participants with Dup2 (UDP = 40, Italy = 26), 61% were classified as DMD, 9% as IMD, and 30% as BMD. Median age at last observation was 15.4 years (interquartile range 8.79–26.0) and 75% had been on corticosteroids for at least 6 months. Age at LOA differed significantly between participants with Dup2 DMD and historical controls without Dup2 DMD (p < 0.001). Valid spirometry was limited but suggested a delay in the typical age-related decline in forced vital capacity and 24 of 55 participants with adequate cardiac data had cardiomyopathy. Discussion Some patients with Dup2 display a milder disease course than controls without Dup2 DMD, and prolonged ambulation with corticosteroids suggests the potential of IRES activation as a molecular mechanism. As Dup2-targeted therapies reach clinical applications, this information is critical to aid in the interpretation of the efficacy of new treatments.

24 October 2023 in Chest
Verified
Journal Article
Closed access
JHJ.D. Hammond
J.D. Hammond
MKMatthew J. Kielt
Matthew J. Kielt
SCSara Conroy
Sara Conroy
KLKrithika Lingappan
Krithika Lingappan
EAEric D. Austin
Eric D. Austin
MGMilenka Cuevas Guaman
Milenka Cuevas Guaman